A multicentre observational study of changes in clinical factors associated with the administration of immune checkpoint inhibitors in gastrointestinal cancer
Not Applicable
Recruiting
- Conditions
- gastric cancer, oesophageal cancer
- Registration Number
- JPRN-jRCT1050220135
- Lead Sponsor
- Inatomi Osamu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 280
Inclusion Criteria
Cases used Nivolumab/Pembrolizumab for unresectable or recurrent gastric and oesophageal cancer from October 2017 to December 2024
Exclusion Criteria
Cases in which treatment was terminated before the start of the second course
Cases where blood tests were not done before the start of the second course
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method